ChromaDex Launches Aggressive Marketing Campaign for BluScience

A new multi-million national media campaign has been launched by Irvine, California’s ChromaDex Corporation (OTCBB:CDXC) for its recently commercialized BluScience™ line of dietary supplements.  The help facilitate the media blitz – which will include television, radio and digital outlets - ChromaDex has retained RJ Palmer, a NYC-based full service media agency with billings in excess of $800 million.  RJ Palmer, a subsidiary of holding company, MDC Partners, provides strategic insights, TV, Print, OOH (Out of Home), radio and online media planning and buying as well as corporate barter and branded entertainment.

The radio campaign began in early March, and the television campaign began this week, said ChromaDex in a statement this morning.

The recently launched (began early in 2012) BluScience™ line is currently consists of HeartBlu - Healthy Heart Support; EternalBlu - Anti-aging Support; TrimBlu - Weight Management Support; and Blu2Go - Focus & Energy Melt.  The novel ingredient in BluScience™ is ChromaDex’s proprietary, patent-pending , branded as pTeroPure®, which was named the 2010 North American Most Promising Ingredient of the Year by the independent research company, Frost & Sullivan.  Pterostilbene is a stilbenoid that is naturally found in blueberries and thought to exhibit anti-cancer, anti-hypercholesterolemia, anti-hypertriglyceridemia properties, as well as fight off and reverse cognitive decline.  One capsule of BluScience™ has the equivalent amount of pterostilbene as contained in more than 500 cartons of blueberries.

These products are now available at GNC stores, Walgreens, online at and at thousands of other drugstores and pharmacies through a distribution agreement with healthcare services industry stalwart McKesson Corporation (NYSE:MCK).  ChromaDex anticipates having its products spread across more than 25,000 retail store by the end of 2012 in addition to major online retailers.

To help fund its new marketing initiatives, on February 10, 2012, ChromaDex closed a common stock sale in which it raised $11.175 million by selling shares at 75 cents each.  There are roughly 91 million shares outstanding.  Shares of CDXC put on a run to kick-off 2012 with the new product launch and rose as high as $1.22 each, but have cooled-off since.  Shares are back down near a support level, closing trading yesterday at 63 cents.

ChromaDex (CDXC) Stock Quote and News:

Disclaimer: Neither nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at


Add your comment

Commenting is allowed only for registered users.

Other articlesgo to homepage

Hard to Overlook Longhai Steel and $608 Million in Revenue in 2011

Hard to Overlook Longhai Steel and $608 Million in Revenue in 2011(0)

Scrolling through another batch of earnings reports from big board companies in the steel business once again showcases the out of sync valuation with Longhai Steel, Inc. (OTCBB: LGHS) and its industry peers. Olympic Steel, Inc., (NASDAQ: ZEUS) reported net sales for the fourth quarter of 2011 totaled $319.9 million, the highest ever for a

Andes Gold Corp. Stock Chart Analysis Video

Andes Gold Corp. Stock Chart Analysis Video(0)

The stock chart for Andes Gold Corporation (Pink Sheets: AGCZ) is in a solid uptrend in 2012; moving from a penny to touch $0.068 in the past two months.  Both the 50 and 200 day simple moving averages are trending upward with the pps holding well above those key markers.  Support is established at $0.05

Stocks Slip at Open on Fourth Quarter GDP

Stocks Slip at Open on Fourth Quarter GDP(0)

The U.S. economy expanded in the fourth quarter of 2011 basically right in line with economists’ predictions.  In the Commerce Department’s final estimate released this morning, gross domestic product (GDP) increased at a 3.0 percent annual rate in the final quarter after a 1.8 percent growth rate during the third quarter.  This is the fastest

Salamon Group Lands New Solar Projects

Salamon Group Lands New Solar Projects(0)

Solar energy company Salamon Group, Inc. (OTCQB: SLMU) reported that it secured the rights to build solar power systems on the rooftops of 23 schools in Williamson County Tennessee.   The Las Vegas-based company will immediately start building 3 solar power systems with an output of 200 kilowatts each, which will equate to $3.3 million in

Optimer and Astellas Partner on Clostridium Difficile Infection Drug

Optimer and Astellas Partner on Clostridium Difficile Infection Drug(0)

San Diego, California-based Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Tokyo-based Astelllas Pharma Inc. (Pink Sheets: ALPMY, Tokyo: 4503) reported this morning that the execution of an exclusive collaboration and license agreement to develop and commercialize fidaxomicin tablets in Japan for the treatment of Clostridium difficile Infection (CDI). Fidaxomicin is approved by the U.S. Food and

read more

Stay Informed

Receive the OTCS Newsletter *


* required

Dana-Farber to Host Cellceutix Trials

Cellceutix Corporation (CTIX)
Cellceutix Corporation has filed its Investigational New Drug application with the FDA. Dana-Farber and Beth Israel Deaconess Medical Center will be hosting the clinical trials for Kevetrin, Cellceutix's novel cancer drug. Read more news and get a stock quote.

Diabetes Rate Growing Exponentially

According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.

Contacts and information

Have an opinion or news that you want to share?

Social networks

Most popular categories

© 2011 Viper Enterprises, LLC. All rights reserved.